肿瘤突变负荷：帕博利珠单抗临床获益的新预测指标。
Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.
机构信息
Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Ph.D. Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan.
出版信息
Clin Cancer Res. 2024 Sep 3;30(17):3652-3654. doi: 10.1158/1078-0432.CCR-24-1261.
A recent study evaluated the efficacy of pembrolizumab across various cancers, classified according to tumor mutational load (TML) defined by whole-genome sequencing. Tumors exhibiting intermediate to high TML showed improved clinical benefit from pembrolizumab. This proof-of-concept study highlights clinical value of TML in patient selection, advancing precision immunotherapy and treatment strategies. See related article by Geurts et al., p. 3735.
最近的一项研究评估了帕博利珠单抗在各种癌症中的疗效，这些癌症根据全基因组测序定义的肿瘤突变负荷（TML）进行分类。表现出中高 TML 的肿瘤从帕博利珠单抗治疗中获得了更好的临床获益。这项概念验证研究强调了 TML 在患者选择中的临床价值，推进了精准免疫治疗和治疗策略。见 Geurts 等人的相关文章，第 3735 页。
Zotero 插件